A Hawaii overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
27.0% of Hawaii adults have obesity, per the CDC's 2024 BRFSS data (n=6,251, 95% CI 25.4–28.6) 1. That is up from 23.8% in 2016: Hawaii still ranks among the lowest-obesity states, and the rate has climbed roughly three points in under a decade 1.
The statewide average hides the more important number. Obesity prevalence is 51.9% among Native Hawaiian and Pacific Islander adults versus 18.9% among Asian adults 2, one of the starkest disparities in any state's BRFSS breakdown.
No. Hawaii Medicaid (Med-QUEST, delivered through QUEST Integration managed-care plans) does not cover GLP-1/GIP drugs for obesity or chronic weight management.
This is confirmed directly in Kaiser Permanente Hawaii's QUEST Drug Formulary, effective August 1, 2026: semaglutide is covered only as Ozempic (Tier 2, $0, the type 2 diabetes label) and liraglutide only as Victoza (Tier 1, $0, also diabetes-labeled). Generic phentermine is covered. Wegovy, Zepbound, Saxenda, Mounjaro, and the word tirzepatide do not appear anywhere in the 90-page document 5.
AlohaCare, a second QUEST managed-care plan, corroborates the boundary directly: it covers all medically necessary Med-QUEST-covered medications 6, meaning plan coverage is bounded by what the state program itself covers. This reflects state policy, not one plan's idiosyncratic choice. Coverage was directly verified for two of Hawaii's five QUEST plans 7.
Net effect: an enrollee with type 2 diabetes can get Ozempic or Victoza at $0, and an enrollee seeking a GLP-1 for obesity has no state-covered option today. A member can still pursue a non-formulary medical-necessity exception, which is not the same as a standing weight-management benefit.
Hawaii is an unusual market for cash-pay care. The uninsured rate is roughly 3.5% and median household income is 00,745 (ACS 2024 1-year, MOE ± ,760) 4, so a cash offer here competes against near-universal existing coverage rather than a large uninsured population. What it competes with specifically is a coverage gap: insured, but not for this.
Astra's price in Hawaii is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Hawaii price and no shipping-distance surcharge.
Not yet verified. Hawaii-specific telehealth prescribing rules were not confirmed against a primary source in this pass, so this page does not state them. The Hawaii Board of Medical Examiners is the regulator to check for current requirements: cca.hawaii.gov/pvl/boards/medical/.
What is settled: GLP-1 prescribing for weight management is handled by primary care and telehealth clinicians, not exclusively endocrinologists or bariatric specialists.
Astra serves patients in all 50 states, Hawaii included, across a population of 1,446,146 3 spread over multiple islands. Visits and refills are handled online, and medication ships from a state-licensed US compounding pharmacy.
Honolulu has its own page below.
Astra treats patients in Hawaii through state-licensed physicians.
City-level detail for Hawaii.
No. Hawaii's Med-QUEST Medicaid program covers semaglutide and liraglutide only under their diabetes-labeled brand names (Ozempic and Victoza, both $0 copay) — not for obesity or weight management. Wegovy, Zepbound, Saxenda, and Mounjaro don't appear on the state's managed-care formularies at all. Generic phentermine is covered. A member could still request a non-formulary medical-necessity exception, but there's no standing weight-management drug benefit today.
The same as everywhere Astra operates: $68/month for semaglutide or $118/month for tirzepatide, both on 12-month plans billed annually ($816 and $1,416 total). There's no Hawaii-specific price or local discount — see the Honolulu page for what local clinics currently publish, for comparison.
No. GLP-1 prescribing for weight management is handled by primary care and telehealth clinicians, not exclusively endocrinologists or bariatric specialists. With patients spread across multiple islands and often far from an in-person specialist, telehealth is frequently the more practical path to an initial consult and ongoing prescription management.
Yes. Astra is licensed to treat patients in all 50 states, including Hawaii.
Local, source-verified pricing is tracked at the city level. See the Honolulu page for specific clinic prices, structures, and the dates they were checked.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.